Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXA-201 versus levofloxacin for complicated urinary tract infection including pyelonephritis
2010-023453-11Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in complicated urinary tract infection (cUTI) and pyelonephritis comparing CXA-201 intravenous arm with Levofloxacin intravenous arm (2 arms). Primary endpoint: Microbiological response rate in the microbiologically evaluable population at the test-of-cure visit. Started Apr 2011; status: completed.
02
Drugs
ceftolozane + tazobactamlevofloxacin
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on 2010-023453-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023453-11.